Sequence polymorphisms of Plasmodium vivax ookinete surface proteins (Pvs25 and Pvs28) from clinical isolates in Korea

Tropical Medicine and International Health

Volumn 15, Issue 9, 2010, Pages 1072-1076

  Han, Eun Taek ^a   Lee, Won Ja ^b   Sattabongkot, Jetsumon ^c   Jang, Jin Woo ^d   Nam, Myoung Hyun ^d   An, Seong Soo A ^e   Suh, Inbum ^a   Lim, Chae Seung ^d  

^a Kangwon National University   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d Korea University College of Medicine   (South Korea)

^e Gachon University College of Medicine   (South Korea)

Author keywords

Malaria vaccine; Ookinete surface protein; Plasmodium vivax; Pvs25; Pvs28

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ALLELE; AMINO ACID; ANTIGEN; DISEASE TRANSMISSION; FREQUENCY ANALYSIS; PARASITIC DISEASE; POLYMORPHISM; PROTEIN; VACCINATION;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE AMPLIFICATION; GENE FREQUENCY; GENE SEQUENCE; KOREA; MUTATOR GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE ISOLATION; PLASMODIUM VIVAX; POLYMERASE CHAIN REACTION; PVS25 GENE; PVS28 GENE; SEQUENCE ANALYSIS; TANDEM REPEAT;

AMINO ACID SEQUENCE; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; DNA PRIMERS; DNA, PROTOZOAN; HUMANS; MALARIA VACCINES; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PLASMODIUM VIVAX; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REPUBLIC OF KOREA;

PLASMODIUM VIVAX; TULIP BREAKING VIRUS;

EID: 77955352015     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2010.02574.x     Document Type: Article

References (9)

1. Escalante AA, Cornejo OE, Freeland DE et al. (2005) A monkey tales: the origin of Plasmodium vivax as a human malaria parasite. Proceedings of National Academy Science of USA 102, 1980 1985.
2. González-Cerón L, Alvarado-Delgado A, Martínez- Barnetche J et al. (2010) Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity. Infection Genetics and Evolution 10, 645 654.
3. Kaslow DC (1992) Transmission-blocking immunity against malaria and other vector-borne diseases. Current Opinion in Immunology 5, 557 565.
4. Malkin EM, Durbin AP, Diemert DJ et al. (2005) Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23, 3131 3138.
5. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ Anstey NM (2007) Vivax malaria: neglected and not benign. American Journal of Tropical Medicine and Hygiene 77, 79 87.
6. Sattabongkot J, Tsuboi T, Hisaeda H et al. (2003) Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. American Journal of Tropical Medicine and Hygiene 69, 536 541.
7. Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM Torii M (1998) Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Molecular Medicine 4, 772 782.
8. Tsuboi T, Kaneko O, Cao YM et al. (2004) A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28. Parasitology International 53, 211 216.
9. Zakeri S, Razavi S Djadid ND (2009) Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran. Acta Tropica 109, 176 180.